Background: Pneumonia remains a leading cause of antibiotic consumption globally, contributing significantly to the burden of antimicrobial resistance (AMR). The respiratory microbiome plays a crucial role in the emergence of AMR and therapeutic failure in both community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). The PHENOMENON study aims to investigate the relationship between the respiratory microbiome composition and clinical outcomes to improve the prediction of treatment failure and AMR emergence. Methods: This multicenter prospective cohort study will include 300 adult patients across three cohorts: CAP in general wards, severe CAP in intensive care units (ICU), and ventilator-associated HAP (vHAP/VAP). Patients will undergo oropharyngeal and rectal swabbing at admission (Day 0), Day 3, Day 7-10, and Day 90, along with blood sampling and endotracheal aspirates in intubated patients. The primary objective is to assess the association between baseline respiratory microbiome composition and time to antibiotic response within 7-10 days. The composite primary endpoint includes clinical failure, microbiological failure, or AMR emergence. Secondary endpoints explore the association between microbiome composition and pneumonia recurrence, severity, hospital length of stay, and mortality at Day 28 and Day 90. Expected Outcomes: This study will provide insights into the predictive value of respiratory microbiome composition on antibiotic response and AMR emergence. Understanding these relationships may guide personalized antibiotic strategies and optimize pneumonia management, ultimately reducing treatment failure rates and improving patient outcomes.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Timeframe: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Timeframe: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Timeframe: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Timeframe: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Timeframe: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Timeframe: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Timeframe: 3 months